Patents
Literature
38 results about "Human liver" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The liver is a vital organ normally present in humans, in the upper right quadrant of the abdomen. The liver has a wide range of functions, including detoxification of various metabolites, protein synthesis, and the production of biochemicals necessary for digestion. The liver is necessary for survival, and there is currently no way to compensate for the absence of liver function in the long term, although liver dialysis techniques can be used in the short term. The liver is a gland and plays a major role in metabolism with numerous functions in the human body, including regulation of glycogen storage, decomposition of red blood cells, plasma protein synthesis, hormone production, and detoxification. The liver lies below the diaphragm in the abdominal-pelvic region of the abdomen. It produces bile, an alkaline compound which aids in digestion via the emulsification of lipids. The liver's highly specialized tissue consisting of mostly hepatocytes regulates a wide variety of high-volume biochemical reactions, including the synthesis and breakdown of small and complex molecules, many of which are necessary for normal vital functions.
Construction method and application of human acute liver injury and chemotaxis model based on normal liver organoids
The present application relates to a method for constructing a human acute liver injury and chemotaxis model based on a normal liver organoid and application thereof. Specifically, the present application provides a method for constructing a human liver organoid; further, contacting the liver organoid with a hepatotoxic drug can construct a human acute liver injury model; co-culturing the organoid or the injury model with immune cells can construct an in vitro immune cell chemotaxis model. The present application also provides reversible immunoaffinity magnetic beads for isolating VSIG4-positive macrophages and a method for isolating the same. The human liver organoid, acute liver injury model and chemotaxis model of the present application can be used for screening drugs for treating acute liver injury, evaluating the hepatotoxicity of compounds, researching the pathogenesis of acute liver injury and evaluating the effect of immunomodulatory drugs.
Owner:SHANGHAI TONGJI HOSPITAL
Compartmental analysis of extracorporeal liver perfusion systems
PCT designated stageWO2026055242A9Other blood circulation devicesControl devicesCholic acidLiver function
Methods are provided for effectively distinguishing the abilities of a human liver and an extracorporeal liver in an extracorporeal liver perfusion system to extract cholate and, thus, measure relative liver function.
Owner:HEPQUANT LLC
A method, apparatus, system, and medium for predicting drug hepatotoxicity
The application provides a drug hepatotoxicity prediction method, device, system and medium, the method comprising: sequencing human liver cells after being contacted with a drug to be predicted to obtain a genome expression profile of the human liver cells after being contacted with the drug to be predicted; calculating the sum of the absolute values of the fold changes of the genes in the current gene pathway as the toxicity score of the current gene pathway according to the expression profile; calculating the Z value of the current gene pathway according to the toxicity score of the current gene pathway, the average value and the standard deviation value of the toxicity scores of the gene pathways calculated multiple times by a plurality of preset gene pathways; and predicting that the drug to be predicted has hepatotoxicity when the Z value is greater than 1.5. Therefore, the application can accurately, timely, effectively and sensitively predict drug hepatotoxicity without a large number of living animals as an experimental basis, and has good advantages in safety, environmental protection and animal protection. The application has the advantages of short experimental period and low cost.
Owner:CAPITALBIO CORP +2
AAVR knockout mouse in combination with human liver chimerism and methods of use and production of the same
PendingUS20260007122A1Compounds screening/testingCell receptors/surface-antigens/surface-determinantsImmune compromisedKnockout animal
The present disclosure provides an immunodeficient or immune-impaired chimeric non-human animal with a deletion or impairment of adeno-associated virus receptor (AAVR), comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to evaluate transduction efficiency of adeno-associated viruses (AAV), and determine mechanism of inhibition / modification of AAV transduction in human hepatocytes.
Owner:AVACHROME INC
Preparation method and application of large-size human liver organoids
The application discloses a preparation method and application of large-size human liver organoids, and belongs to the technical field of cell culture. In the application, 2D culture mature human primary liver parenchymal cells with different cell amounts are resuspended by using a hepatocyte maturation medium HIM, and are added into a U-shaped bottom 96-hole plate for low-oxygen static culture. After the cells are aggregated, the cells are cultured in normal oxygen and are shaken, so that large-size human liver organoids with different cell contents are prepared. The method does not need biological materials, and can induce human primary liver parenchymal cells to self-assemble and construct functional liver organoids with high uniformity in scale through specific culture conditions. The method solves the problems of large batch difference, high heterogeneity and dedifferentiation in the prior art, and can be widely applied to drug hepatotoxicity testing, in-vitro modeling of liver diseases and development of a bioartificial liver system.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Application of ginsenoside Rg1 in preparation of product for treating oxaliplatin-induced liver injury
The invention discloses application of ginsenoside Rg1 in preparation of a product for treating oxaliplatin-induced liver injury, and belongs to the technical field of medicines. Experimental verification shows that after ginsenoside Rg1 is administrated, the survival rate of HL-7702 human hepatocytes induced by oxaliplatin is increased, the content of transaminase indexes AST and ALT in the cells is obviously reduced, the content of active oxygen is obviously reduced, and the condition of mouse liver injury can be obviously improved. The experimental results show that the ginsenoside Rg1 can improve the liver injury induced by oxaliplatin, and a new technical thought is provided for preparing the product for treating the liver injury induced by oxaliplatin.
Owner:DALIAN NATIONALITIES UNIVERSITY
Vinegar guide as well as formula and preparation method thereof
The invention relates to a vinegar guide as well as a formula and a preparation method thereof. The invention relates to a vinegar guide, which is a formula vinegar beverage and seasoning which can be directly taken orally. The vinegar guide takes original vinegar as a base material, and components are selected from substances which are allowed to be used according to a traditional food and traditional Chinese medicinal material catalog published by the country. Adding drinking water according to a ratio, performing high-temperature (sterilization) to stimulate the properties of medicinal and edible substances, performing low-temperature decoction to overflow effective components, and performing seasoning. The requirements of related laws and technical specifications such as Food Safety Law of the People's Republic of China are met. According to the theory of'guiding medicine to channel 'of Chinese traditional medicine and pharmacy, medicinal and edible Chinese herbal medicines are soaked in vinegar and decocted with water, so that material attribute components can be effectively stimulated to directly act on human liver and stomach visceral meridians, and the requirement of human organs on absorption of the medicinal and edible material attribute components is met. And meanwhile, the health-care wine can effectively eliminate or relieve discomfort of a human body caused by drinking.
Owner:魏铁汉
A method for constructing a 3D-printed liver organoid scaffold loaded with fh1 alginate sodium microspheres assembled mesenchymal stem cells
The application discloses a construction method of a 3D printing liver organoid support loaded with mesenchymal stem cells assembled by FH1 sodium alginate microspheres, and comprises the following steps: preparing CaO2@ZIF-8@SL; preparing FH1-loaded sodium alginate microspheres FH1@SA; and preparing a 3D printing liver organoid support. The 3D printing liver organoid support prepared by the method can significantly enhance the differentiation of human umbilical cord mesenchymal stem cells into functional stem cells, and can be used for constructing a human liver organoid model.
Owner:NINGXIA MEDICAL UNIVERSITY GENERAL HOSPITAL
NON-HUMAN CHIMERATIVE ANIMAL WITH HUMAN LIVER DEFICIENCED IN P450 OXIDOREDUCTASE AND METHOD FOR USE THEREMISH
Owner:BAYLOR COLLEGE OF MEDICINE
Human liver vessel blood flow simulation method based on deep learning
The invention relates to the technical field of blood flow simulation, in particular to a human liver blood vessel blood flow simulation method based on deep learning, and the method comprises the steps: reconstructing an original liver blood vessel medical image to obtain a water tightness STL model of a liver blood vessel; then an open source solver OpenFOAM is used for conducting analysis domain division on the model, and information of a blood flow velocity field and a pressure field is obtained through solving; performing data preprocessing, performing time sequence processing on the data to obtain a data form suitable for the PBTCNN, and inputting the data into the PBTCNN for training; and finally, storing the trained model for predicting a pressure field and a velocity field. The PBTCNN realizes partial replacement of a traditional CFD method for hemodynamic analysis, can reduce the cost of blood flow simulation, does not need to reduce the calculation cost based on the characteristics of grid division, and can obtain a blood flow simulation result more quickly while guaranteeing the precision.
Owner:QINGDAO EMIBOCHUANG MEDICAL TECH CO LTD
A method for rapid determination of tigecycline and GD-MET-1 in human liver microsomal incubation system by LC-MS / MS
This invention belongs to the field of drug metabolism and analytical chemistry, specifically relating to a method for the rapid determination of tigustastat and its active metabolite GD-MET-1 concentrations in a human liver microsome incubation system using liquid chromatography-tandem mass spectrometry (LC-MS / MS). The method first prepares stock solutions of tigustastat, GD-MET-1, and an internal standard, and prepares a series of standard curve solutions, quality control solutions, and precipitant solutions containing the internal standard. Next, the sample with the added precipitant solution undergoes vortexing and centrifugation pretreatment. Finally, chromatographic and mass spectrometric conditions are set, and the analysis is performed by LC-MS / MS. This method has been validated for specificity, accuracy, precision, matrix effects, recovery, residues, and stability, and can be reliably used for metabolic stability studies of tigustastat and GD-MET-1 in a human liver microsome incubation system, GD-MET-1 formation studies, metabolic enzyme identification, enzyme kinetic studies, and drug interaction studies.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Tri-fused ring compound and application thereof
The invention discloses a tricyclic compound and application thereof, and belongs to the technical field of medicine synthesis. The invention provides a tricyclic compound as shown in a formula I. The tricyclic compound can be used for broad-spectrum virus resistance, can effectively inhibit the activity of SARS-CoV, MERS-CoV, SARS-CoV-2 and other coronaviruses and block the replication of the viruses in the body of a patient, and particularly has more advantages in the aspects of pharmacokinetic property, human CYP inhibition rate, cytotoxicity, human liver microsome stability and the like. The compound disclosed by the invention can be used as a generic coronavirus resisting drug, and particularly provides a new choice for developing a drug for preventing and treating diseases related to novel coronavirus infection. Formula I
Owner:SICHUAN UNIV
A dimer compound with endothelin A (ETA) receptor antagonist activity and its application
This invention belongs to the field of medicinal chemistry, specifically relating to a dimeric compound with endothelin A (ETA) receptor antagonist activity and its applications. The compound of this invention is rapidly metabolized to atrasentan in human liver microsomes. In rats, after oral administration, it exhibits excellent absorption, high bioavailability, and a long half-life, significantly lowering blood pressure and improving kidney injury. Furthermore, its weak binding to P-GP and its non-substrate nature further enhance its bioavailability. The compound of this invention, or its pharmaceutically acceptable salt, holds promise for use in the preparation of drugs for the treatment and prevention of ETA receptor antagonist-related diseases, such as chronic kidney disease and hypertension.
Owner:JIANG SU PHARMAMAXCORP
Human liver metastasis-derived colon cancer cell line crc-x1 and use thereof
PendingCN122104594AMicrobiological testing/measurementArtificial cell constructsOncologyCancer research
The human liver metastasis-derived colon cancer cell line CRC-X1 and its application belong to the field of microbial animal cell lines. The human colon cancer cell line is named Homo sapiens CRC-X1, and was preserved in the China Center for Type Culture Collection on November 22, 2025, with the preservation number CCTCC NO: C2025354. The human liver metastasis-derived colon cancer cell line CRC-X1 can be applied in the establishment of a cell model of colon cancer occurrence, development or metastasis; CRC-X1 can be applied in the cell model of studying the differentiation mechanism of colon cancer, cell morphology and functional abnormalities, tumor infiltration and metastasis mechanism, and guiding clinical comprehensive diagnosis and treatment. CRC-X1 can be applied in the study of the mechanism of colon cancer and the screening of drugs for preventing and treating colon cancer. CRC-X1 can be applied in the establishment of an animal model of colon cancer.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY
Two-sided needle base tetracyclic analogs-sulfonamide hybrids and their preparation and application
This invention discloses a tetracyclic analogue-sulfonamide hybrid of *Zanthoxylum bungeanum* alkaloids, possessing the following general formula. The invention also provides a method for preparing the tetracyclic analogue-sulfonamide hybrid of *Zanthoxylum bungeanum* alkaloids, comprising dissolving compound 10 or compound 11 and triethylamine in dichloromethane, adding benzenesulfonyl chloride derivative 12a-12e at low temperature, stirring, and then stirring at room temperature until the starting material spot disappears. The reaction is monitored by TLC. After the reaction is complete, the product 13a-13e or 14a-14e is obtained by column chromatography separation and purification. The tetracyclic analogue-sulfonamide hybrid of *Zanthoxylum bungeanum* alkaloids provided by this invention has been shown in in vitro antitumor experiments to exhibit strong inhibitory effects on human cervical cancer cells in leukemia cells, human liver cancer cells, human lung cancer cells, human cervical cancer cells, and normal human liver cells.
Owner:GUANGXI UNIV OF CHINESE MEDICINE
Method and device for identifying thrombi in the portal vein system
ActiveCN120823632BSubcutaneous biometric featuresBlood vessel patternsPortal venous systemImaging processing
The application discloses a kind of hepatic portal vein system thrombus identification method and device, it is related to medical image processing technical field, wherein the method comprises: the CTA image to be handled is input to rough segmentation model, and the output blood vessel cavity;Blood vessel cavity includes blood vessel and thrombus in blood vessel;Rough segmentation model is obtained by training nnunet network;The HU value distribution of pixel in the blood vessel cavity is counted, combined with human liver tissue standard HU value, determine the segmentation threshold for segmenting thrombus;Based on density clustering algorithm, determine the cluster center coordinates of thrombus in the blood vessel;With cluster center coordinates as seed point, according to the similarity of pixel HU value in blood vessel cavity and the segmentation threshold, region growth is carried out, until encountering blood vessel boundary or there is no pixel point to be grown, obtain fine segmentation result;The fine segmentation result includes each pixel where thrombus is located.The application can improve the accuracy of hepatic portal vein system thrombus identification.
Owner:GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY +1
Antibodies that bind to human NTCP and can inhibit hepatitis B virus (HBV) infection of human liver cells.
The present invention provides a NTCP-binding antibody capable of inhibiting infection of human hepatocytes with hepatitis B virus (HBV) particles. The present invention also provides a NTCP-binding antibody that is capable of inhibiting infection of human hepatocytes with hepatitis B virus (HBV) particles and that reduces the effect of NTCP on transport of bile acid.
Owner:THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH +2
Pre-transplantation evaluation of human livers using optical coherence tomography
Apparatus and associated methods relate to a pre-transplantation evaluation of human livers using optical coherence tomography. In an illustrative example, a computer-implemented method performed by at least one processor to conduct a non-invasive evaluation of a liver prior to a transplantation procedure. The method includes providing a polarization-sensitive optical coherence tomography (PS-OCT) system. The PS-OCT system may, for example, be coupled to a machine-learning-based system trained to evaluate PC-OCT images of liver. The method may, for example, include determining steatosis, fibrosis, inflammation, and necrosis scores for the liver. The method may, for example, determine whether the liver is unsuitable or suitable for use as a donor liver when the steatosis, fibrosis, inflammation, and necrosis scores fail to meet predetermined donor suitability criteria; and, maintaining the liver under proper preservation conditions when the liver is determined to be suitable for use as a donor liver.
Owner:THE BOARD OF RGT UNIV OF OKLAHOMA
Amyloid β accumulation model animal
PCT designated stageWO2026029135A1Microbiological testing/measurementArtificial cell constructsNeuro-degenerative diseaseAmyloid
[Problem] To provide amyloid β accumulation model cells. [Solution] A neurodegenerative disease model tissue and model animal, comprising brain cells derived from a non-human animal in which all or a part of a liver is replaced with human liver cells.
Owner:PHOENIXBIO
An organoselenium composition for inhibiting tumor cells and its preparation method
This invention belongs to the field of biomedical technology, specifically relating to an organic selenium composition for inhibiting tumor cells and its preparation method. The organic selenium composition comprises the following components in parts by weight: 7-12 parts selenobenzonitrile-glycyrrhizinamide, 2-5 parts trazastilbene, and 0.5-1 part selenized carrageenan. This invention utilizes the reaction of the carbonyl α,β-unsaturated olefin bond in methyl glycyrrhizinic acid with 4-mercaptobenzonitrile to introduce a benzonitrile structure to enhance targeting while retaining the core active structure of methyl glycyrrhizinic acid. Simultaneously, a selenium compound is introduced onto the carboxyl group of methyl glycyrrhizinic acid, thereby preparing selenobenzonitrile-glycyrrhizinamide. When selenobenzonitrile-glycyrrhizinamide is used in combination with trazastilbene and selenized carrageenan, the prepared organic selenium composition exhibits significant inhibitory effects on the proliferation of various tumor cells, while showing no significant toxicity to normal human liver cells (L02).
Owner:XIAMEN BLUE BAY SCI & TECH CO LTD
Application of artemisinene with double functions in promoting liver cell maturation and relieving liver lipid metabolism dysfunction
The invention belongs to the technical field of biological medicines, and discloses application of artemisinene with double functions in promoting liver cell maturation and relieving liver lipid metabolism dysfunction. It is found for the first time that ATT can specifically and efficiently promote human hepatic progenitor cell organoids to differentiate into functional mature hepatic cells, the effect of ATT depends on activation of a cAMP-EPAC signal channel, and the action mechanism and effect are remarkably different from those of a DHA-based scheme in the prior art. Meanwhile, the ATT can obviously relieve lipid deposition of liver cells, improve lipid metabolism disorder, effectively relieve liver cell oxidative stress and lipid peroxidation damage induced by lipid deposition, and prevent the cells from triggered apoptosis.
Owner:GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)
Benzoheterocycle compound, pharmaceutical composition containing benzoheterocycle compound and application of benzoheterocycle compound
The invention provides a benzoheterocycle compound, a pharmaceutical composition containing the benzoheterocycle compound and application of the benzoheterocycle compound, and particularly relates to a compound shown in the following formula I, pharmaceutically acceptable salt, stereoisomer, deuterated compound, solvate, prodrug or metabolite of the benzoheterocycle compound, a pharmaceutical composition containing the benzoheterocycle compound and application of the benzoheterocycle compound. The compound disclosed by the invention is a WRN regulating agent with a novel structure, has strong WRN inhibitory activity and MSI HCT116 cell proliferation inhibitory activity, shows excellent selectivity in anti-proliferation activity evaluation of MSI cells HCT116 and MSS cells SW620, shows relatively good stability in in-vitro human liver microsome, has better druggability, and can be applied to preparation of anti-proliferative drugs of human liver microsome, such as liver microsome anti-proliferative drugs, liver microsome anti-proliferative drugs, liver microsome anti-proliferative drugs, liver microsome anti-proliferative drugs, liver microsome anti-proliferative drugs and liver microsome anti-proliferative drugs. The compound can be used as a WRN regulating agent for preparing medicines for preventing or treating diseases related to WRN.
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
Wearable bioartificial liver structure
The utility model discloses a wearable bioartificial liver structure. The wearable bioartificial liver structure comprises a liquid circulation pipeline and a biological liver circulation pipeline, wherein the blood circulation pipeline comprises a blood input pipe, a first flexible driving part, a membrane type plasma separator and a blood return pipe which are connected in sequence; the biological liver circulation pipeline comprises a second flexible driving part, a membrane type plasma component separator, a cell canning device and a third flexible driving part which are connected in sequence. Wherein the blood circulation pipeline is used for extracting blood out of a body for plasma separation, and the biological liver circulation pipeline is connected with the blood circulation pipeline so as to provide human hepatocyte-like cells required by a human body, and the human hepatocyte-like cells and the separated blood are jointly transfused back into the human body; moreover, the first flexible driving part, the second flexible driving part and the third flexible driving part are all provided with wearing parts so as to be directly worn on a human body. Therefore, the problem that the patient needs to lie in bed for a long time in the treatment period is effectively solved, and the patient can carry the equipment for long-time treatment.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV
Compartmental analysis of extracorporeal liver perfusion systems
PCT designated stageWO2026055242A1Other blood circulation devicesControl devicesCholic acidLiver function
Methods are provided for effectively distinguishing the abilities of a human liver and an extracorporeal liver in an extracorporeal liver perfusion system to extract cholate and, thus, measure relative liver function.
Owner:HEPQUANT LLC
Benzimidazole heteroatom-containing spiro compound and medicinal use thereof
A benzimidazole heteroatom-containing spiro compound and a medicinal use thereof are provided. Activity test results show that the benzimidazole heteroatom-containing spiro compound provided by the present disclosure has a significant antiproliferative activity for human liver tumor cells HepG2, human colon cancer cells HCT116, and / or human gastric adenocarcinoma cells AGS, and most of the compounds involved in the present disclosure exhibit a stronger antiproliferative activity than cisplatin and / or Nutlin-3a. Therefore, the benzimidazole heteroatom-containing spiro compound provided by the present disclosure has a prospect of being developed into an antitumor drug, such as for liver cancer, colon cancer, or gastric cancer.
Owner:CHANGZHI UNIV
A kind of noodles or rice flour of balanced nutrition health care five-zang organ formula and its preparation method
The application discloses a kind of noodles or rice flour of balanced nutrition and health care five viscera food composition and preparation method thereof, and relates to the field of food.The existing market lacks noodles or rice flour food with functional overall balanced nutrition and health care for human liver, heart, spleen, lung and kidney five viscera, which is characterized by being composed of natural food materials with both food and nutrition and health care functions.The composition is compatible for overall comprehensive food nourishment, food tonification and food therapy according to traditional Chinese medicine theory, aiming at human five viscera, to improve human immunity and prevent diseases, in line with the development direction of integrated medicine, and provides diversified nutrition and health care food to meet people's growing health needs.
Owner:赵晓迪
Preparation method and application of large-size human liver organ
The invention discloses a preparation method and application of a large-size human liver organ. Belongs to the technical field of cell culture. The method comprises the following steps: re-suspending 2D cultured mature human primary parenchymal hepatic cells with different cell quantities by using a hepatic cell maturation culture medium HIM, adding the re-suspended cells into a 96-well plate with a U-shaped bottom, carrying out low-oxygen standing culture, and carrying out normal-oxygen shaking culture after the cells are gathered, so as to prepare the large-size human liver organs with different cell contents. According to the method, biological materials are not needed, the human primary parenchymal hepatic cells are induced to be self-assembled through specific culture conditions to construct functional liver organs with highly uniform dimensions, and the problems of large batch difference, high heterogeneity and dedifferentiation in the prior art are solved; the method can be widely applied to drug hepatotoxicity testing, liver disease in-vitro modeling and bioartificial liver system development.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Non-human vertebrate comprising human liver cells transplanted therein and method for producing the same
This invention provides a non-human vertebrate exhibiting a higher human liver cell growth rate, a higher human liver cell replacement rate, and higher histological-physiological human reproducibility than existing non-human vertebrates comprising the human liver transplanted therein and a method for producing such non-human vertebrate. Specifically, the method for producing a transgenic non-human vertebrate comprising human liver cells transplanted therein comprises transplanting human liver cells in a non-human vertebrate that has impaired or lowered immune reactions against humans in the presence of human IL-6 in vivo.
Owner:CENT INST FOR EXPERIMENTAL ANIMALS
Application of nicotiflorin in preparation of medicine for treating metabolism-related fatty liver disease / metabolism-related steatohepatitis disease
The invention belongs to the field of medicines, and discloses application of nicotiflorin in preparation of medicines for treating metabolism-related fatty liver diseases / metabolism-related steatohepatitis diseases. The invention discloses application of nicotiflorin in preparation of a medicine for treating fatty liver diseases related to metabolic dysfunction and application of nicotiflorin in preparation of a medicine for treating hepatic fibrosis or slowing down the development process of hepatic fibrosis. The invention discloses an application of nicotiflorin in preparation of a health care product with an auxiliary protection effect on chemical liver injury. The nicotiflorin can obviously reduce the lipid content of AML-12 cells induced by palmitic acid and obviously reduce the expression of alpha-SMA and Collagen1 of human hepatic stellate cells, so that the activation of LX-2 cells is inhibited, and the liver fibrosis induced by CCl4 is obviously improved.
Owner:CHINA PHARM UNIV
